-
1
-
-
0037393956
-
Discovering risperidone: The LSD model of psychopathology
-
Colpaert FC. Discovering risperidone: the LSD model of psychopathology. Nat Rev Drug Discov. 2003;2(4):315-320.
-
(2003)
Nat Rev Drug Discov
, vol.2
, Issue.4
, pp. 315-320
-
-
Colpaert, F.C.1
-
2
-
-
0038383461
-
Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers
-
Van Schaick EA, Lechat P, Remmerie BM, Ko G, Lasseter KC, Mannaert E. Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clin Ther. 2003;25(6):1687-1699.
-
(2003)
Clin Ther
, vol.25
, Issue.6
, pp. 1687-1699
-
-
van Schaick, E.A.1
Lechat, P.2
Remmerie, B.M.3
Ko, G.4
Lasseter, K.C.5
Mannaert, E.6
-
3
-
-
33845419519
-
Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets
-
Normann C, Schmauss M, Bakri N, Gerwe M, Schreiner A. Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets. Pharmacopsychiatry. 2006;39(6):209-212.
-
(2006)
Pharmacopsychiatry
, vol.39
, Issue.6
, pp. 209-212
-
-
Normann, C.1
Schmauss, M.2
Bakri, N.3
Gerwe, M.4
Schreiner, A.5
-
4
-
-
77953018117
-
Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: A randomized open, prospective study
-
Lim HK, Kim JJ, Pae CU, Lee CU, Lee C, Paik IH. Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study. Neuropsychobiology. 2010;62(2):81-86.
-
(2010)
Neuropsychobiology
, vol.62
, Issue.2
, pp. 81-86
-
-
Lim, H.K.1
Kim, J.J.2
Pae, C.U.3
Lee, C.U.4
Lee, C.5
Paik, I.H.6
-
5
-
-
0028332094
-
Survey on the pharmacodynamics of the new antipsychotic risperidone
-
Megens AA, Awouters FH, Schotte A, et al. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994;114(1):9-23.
-
(1994)
Psychopharmacology (Berl)
, vol.114
, Issue.1
, pp. 9-23
-
-
Megens, A.A.1
Awouters, F.H.2
Schotte, A.3
-
6
-
-
75349090533
-
Risperidone dose for schizophrenia
-
October 7 CD007474
-
Li C, Xia J, Wang J. Risperidone dose for schizophrenia. Cochrane Database Syst Rev. October 7, 2009;(4):CD007474.
-
(2009)
Cochrane Database Syst Rev
, Issue.4
-
-
Li, C.1
Xia, J.2
Wang, J.3
-
7
-
-
0037967387
-
Placebo or active control trials of antipsychotic drugs?
-
Fleischhacker WW, Czobor P, Hummer M, Kemmler G, Kohnen R, Volavka J. Placebo or active control trials of antipsychotic drugs? Arch Gen Psychiatry. 2003;60(5):458-464.
-
(2003)
Arch Gen Psychiatry
, vol.60
, Issue.5
, pp. 458-464
-
-
Fleischhacker, W.W.1
Czobor, P.2
Hummer, M.3
Kemmler, G.4
Kohnen, R.5
Volavka, J.6
-
8
-
-
24344476307
-
Control group bias in randomized atypical antipsychotic medication trials for schizophrenia
-
Woods SW, Gueorguieva RV, Baker CB, Makuch RW. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Arch Gen Psychiatry. 2005;62(9):961-970.
-
(2005)
Arch Gen Psychiatry
, vol.62
, Issue.9
, pp. 961-970
-
-
Woods, S.W.1
Gueorguieva, R.V.2
Baker, C.B.3
Makuch, R.W.4
-
10
-
-
62849099049
-
How effective are second-generation antipsychotic drugs? A meta-analysis of placebocontrolled trials
-
Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebocontrolled trials. Mol Psychiatry. 2009;14(4):429-447.
-
(2009)
Mol Psychiatry
, vol.14
, Issue.4
, pp. 429-447
-
-
Leucht, S.1
Arbter, D.2
Engel, R.R.3
Kissling, W.4
Davis, J.M.5
-
11
-
-
18844472318
-
Risperidone versus typical antipsychotic medication for schizophrenia
-
CD000440
-
Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev. 2003;(2):CD000440.
-
(2003)
Cochrane Database Syst Rev
, Issue.2
-
-
Hunter, R.H.1
Joy, C.B.2
Kennedy, E.3
Gilbody, S.M.4
Song, F.5
-
12
-
-
84921431371
-
Risperidone versus typical antipsychotic medication for schizophrenia
-
CD000440
-
Kennedy E, Song F, Hunter R, Clarke A, Gilbody S. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev. 2000;(2):CD000440.
-
(2000)
Cochrane Database Syst Rev
, Issue.2
-
-
Kennedy, E.1
Song, F.2
Hunter, R.3
Clarke, A.4
Gilbody, S.5
-
13
-
-
79960533801
-
Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: Results of a randomized, flexible-dose, openlabel 1-year follow-up comparison
-
doi: 10.1177/0269881110388332
-
Crespo-Facorro B, Pérez-Iglesias RO, Mata I, et al. Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, openlabel 1-year follow-up comparison. J Psychopharmacol. 2011. doi: 10.1177/0269881110388332.
-
(2011)
J Psychopharmacol
-
-
Crespo-Facorro, B.1
Pérez-Iglesias, R.O.2
Mata, I.3
-
14
-
-
79952289209
-
Risperidone versus other atypical antipsychotics for schizophrenia
-
CD006626
-
Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2011;(1):CD006626.
-
(2011)
Cochrane Database Syst Rev
, Issue.1
-
-
Komossa, K.1
Rummel-Kluge, C.2
Schwarz, S.3
Schmid, F.4
Hunger, H.5
Kissling, W.6
Leucht, S.7
-
15
-
-
58049157203
-
Secondgeneration versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis
-
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Secondgeneration versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41.
-
(2009)
Lancet
, vol.373
, Issue.9657
, pp. 31-41
-
-
Leucht, S.1
Corves, C.2
Arbter, D.3
Engel, R.R.4
Li, C.5
Davis, J.M.6
-
16
-
-
60349086480
-
A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia
-
Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152-163.
-
(2009)
Am J Psychiatry
, vol.166
, Issue.2
, pp. 152-163
-
-
Leucht, S.1
Komossa, K.2
Rummel-Kluge, C.3
-
17
-
-
67650505849
-
The CATIE and CUtLASS studies in schizophrenia: Results and implications for clinicians
-
Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs. 2009; 23(8):649-659.
-
(2009)
CNS Drugs
, vol.23
, Issue.8
, pp. 649-659
-
-
Naber, D.1
Lambert, M.2
-
18
-
-
35048837486
-
The CATIE schizophrenia trial: Results, impact, controversy
-
Manschreck TC, Boshes RA. The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry. 2007;15(5):245-258.
-
(2007)
Harv Rev Psychiatry
, vol.15
, Issue.5
, pp. 245-258
-
-
Manschreck, T.C.1
Boshes, R.A.2
-
19
-
-
71249090407
-
Psychopharmacology and adverse effects of antipsychotic long-acting injections: A review
-
Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry Suppl. 2009;52: S13-S19.
-
(2009)
Br J Psychiatry Suppl
, vol.52
-
-
Taylor, D.1
-
20
-
-
0038149626
-
Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic
-
Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6): 1125-1132.
-
(2003)
Am J Psychiatry
, vol.160
, Issue.6
, pp. 1125-1132
-
-
Kane, J.M.1
Eerdekens, M.2
Lindenmayer, J.P.3
Keith, S.J.4
Lesem, M.5
Karcher, K.6
-
21
-
-
9644257391
-
Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets
-
Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005;15(1): 111-117.
-
(2005)
Eur Neuropsychopharmacol
, vol.15
, Issue.1
, pp. 111-117
-
-
Chue, P.1
Eerdekens, M.2
Augustyns, I.3
Lachaux, B.4
Molcan, P.5
Eriksson, L.6
-
22
-
-
78649903563
-
The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden
-
Willis M, Svensson M, Löthgren M, Eriksson B, Berntsson A, Persson U. The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. Eur J Health Econ. 2010;11(6):585-594.
-
(2010)
Eur J Health Econ
, vol.11
, Issue.6
, pp. 585-594
-
-
Willis, M.1
Svensson, M.2
Löthgren, M.3
Eriksson, B.4
Berntsson, A.5
Persson, U.6
-
23
-
-
79951609794
-
Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: Six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America
-
Apiquian R, Córdoba R, Louzã M. Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America. Neuropsychiatr Dis Treat. 2010;7:19-26.
-
(2010)
Neuropsychiatr Dis Treat
, vol.7
, pp. 19-26
-
-
Apiquian, R.1
Córdoba, R.2
Louzã, M.3
-
24
-
-
76949089882
-
Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries
-
Peuskens J, Olivares JM, Pecenak J, et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin. 2010;26(3):501-509.
-
(2010)
Curr Med Res Opin
, vol.26
, Issue.3
, pp. 501-509
-
-
Peuskens, J.1
Olivares, J.M.2
Pecenak, J.3
-
25
-
-
77950944922
-
Safety and efficacy of long-acting injectable risperidone in daily practice: An open-label, noninterventional, prospective study in schizophrenia and related disorders
-
Parellada E, Kouniakis F, Siurkute A, Schreiner A, Don L. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders. Int Clin Psychopharmacol. 2010;25(3):149-154.
-
(2010)
Int Clin Psychopharmacol
, vol.25
, Issue.3
, pp. 149-154
-
-
Parellada, E.1
Kouniakis, F.2
Siurkute, A.3
Schreiner, A.4
Don, L.5
-
26
-
-
33746676344
-
Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity
-
Rubio G, Martinez I, Ponce G, Jimenez-Arriero MA, Lopez-Munoz F, Alamo C. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry. 2006;51(8):531-539.
-
(2006)
Can J Psychiatry
, vol.51
, Issue.8
, pp. 531-539
-
-
Rubio, G.1
Martinez, I.2
Ponce, G.3
Jimenez-Arriero, M.A.4
Lopez-Munoz, F.5
Alamo, C.6
-
27
-
-
41049103316
-
Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis
-
Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus D, Rabinowitz J. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis. J Clin Psychopharm. 2008;28(2):210-213.
-
(2008)
J Clin Psychopharm
, vol.28
, Issue.2
, pp. 210-213
-
-
Emsley, R.1
Medori, R.2
Koen, L.3
Oosthuizen, P.P.4
Niehaus, D.5
Rabinowitz, J.6
-
28
-
-
71249128749
-
Second-generation antipsychotic long-acting injections: Systematic review
-
Fleischhacker WW. Second-generation antipsychotic long-acting injections: systematic review. Br J Psychiatry Suppl. 2009;52:S29-S36.
-
(2009)
Br J Psychiatry Suppl
, vol.52
-
-
Fleischhacker, W.W.1
-
29
-
-
0022386130
-
Childhood schizophrenia: A review and comparison of adult onset schizophrenia
-
Beitchman JH, Childhood schizophrenia: a review and comparison of adult onset schizophrenia. Psychiatric Clin North Am. 1985;8(4): 793-814.
-
(1985)
Psychiatric Clin North Am
, vol.8
, Issue.4
, pp. 793-814
-
-
Beitchman, J.H.1
-
30
-
-
63449085188
-
Risperidone: A review of efficacy studies in adolescents with schizophrenia
-
Madaan V. Risperidone: a review of efficacy studies in adolescents with schizophrenia. Drugs Today (Barc). 2009;45(1):55-62.
-
(2009)
Drugs Today (Barc)
, vol.45
, Issue.1
, pp. 55-62
-
-
Madaan, V.1
-
31
-
-
70350546566
-
A 6-week, randomized, double blind, placebo controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia
-
Haas M, Unis AS, Armenteros J, Copenhaver MD, Quiroz JA, Kushner SF. A 6-week, randomized, double blind, placebo controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol. 2009;19(6):611-621.
-
(2009)
J Child Adolesc Psychopharmacol
, vol.19
, Issue.6
, pp. 611-621
-
-
Haas, M.1
Unis, A.S.2
Armenteros, J.3
Copenhaver, M.D.4
Quiroz, J.A.5
Kushner, S.F.6
-
32
-
-
50949132203
-
Comparison of two risperidone dose ranges inadolescents with schizophrenia
-
[abstract], October 23-28, Boston, MA
-
Pandina G, Kushner S, Singer J, et al. Comparison of two risperidone dose ranges inadolescents with schizophrenia [abstract]. 54th Annu Meet Am Acad Child Adolesc Psychiatry. October 23-28, 2007; Boston, MA.
-
(2007)
54th Annu Meet Am Acad Child Adolesc Psychiatry
-
-
Pandina, G.1
Kushner, S.2
Singer, J.3
-
33
-
-
29944441899
-
Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders
-
Hellings JA, Zarcone JR, Valdovinos MG, Reese RM, Gaughan E, Schroeder SR. Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2005;15(6):885-892.
-
(2005)
J Child Adolesc Psychopharmacol
, vol.15
, Issue.6
, pp. 885-892
-
-
Hellings, J.A.1
Zarcone, J.R.2
Valdovinos, M.G.3
Reese, R.M.4
Gaughan, E.5
Schroeder, S.R.6
-
34
-
-
0032431939
-
Use of atypical neuroleptics in child and adolescent psychiatry
-
Toren P, Loar N, Weizman A. Use of atypical neuroleptics in child and adolescent psychiatry. J Clin Psychiatry. 1998;59(12):644-656.
-
(1998)
J Clin Psychiatry
, vol.59
, Issue.12
, pp. 644-656
-
-
Toren, P.1
Loar, N.2
Weizman, A.3
-
35
-
-
0030943723
-
Risperidone in adolescents with schizophrenia:An open pilot study
-
Armenteros JL, Whitaker AH, Welikson M, Stedge DJ, Gorman J. Risperidone in adolescents with schizophrenia:an open pilot study. J Am Acad Child Adolesc Psychiatry. 1997;36(5):694-700.
-
(1997)
J Am Acad Child Adolesc Psychiatry
, vol.36
, Issue.5
, pp. 694-700
-
-
Armenteros, J.L.1
Whitaker, A.H.2
Welikson, M.3
Stedge, D.J.4
Gorman, J.5
-
36
-
-
0029125796
-
Case study: Risperidone in children and adolescents with schizophrenia
-
Quintana H, Keshavan M. Case study: risperidone in children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 1995;34(10):1292-1296.
-
(1995)
J Am Acad Child Adolesc Psychiatry
, vol.34
, Issue.10
, pp. 1292-1296
-
-
Quintana, H.1
Keshavan, M.2
-
37
-
-
28444479788
-
Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents
-
Correll CU, Penzer JB, Parikh UH, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatric Clin N Am. 2006;15(1):177-206.
-
(2006)
Child Adolesc Psychiatric Clin N Am
, vol.15
, Issue.1
, pp. 177-206
-
-
Correll, C.U.1
Penzer, J.B.2
Parikh, U.H.3
-
38
-
-
0031722498
-
Predictors of medication compliance after hospital discharge in adolescent psychiatric patients
-
Lloyd A, Horan W, Borgaro SR, Stokes JM, Pogge DL, Harvey PD. Predictors of medication compliance after hospital discharge in adolescent psychiatric patients. J Child Adolesc Psychopharmacol. 1998;8(2):133-141.
-
(1998)
J Child Adolesc Psychopharmacol
, vol.8
, Issue.2
, pp. 133-141
-
-
Lloyd, A.1
Horan, W.2
Borgaro, S.R.3
Stokes, J.M.4
Pogge, D.L.5
Harvey, P.D.6
-
39
-
-
70049104227
-
Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia
-
CD006324
-
Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev. 2009;(3):CD006324.
-
(2009)
Cochrane Database Syst Rev
, Issue.3
-
-
Cipriani, A.1
Boso, M.2
Barbui, C.3
-
40
-
-
65349163482
-
Does the addition of a second antipsychotic drug improve clozapine treatment?
-
Barbui C, Signoretti A, Mulè S, Boso M, Cipriani A. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull. 2009;35(2):458-468.
-
(2009)
Schizophr Bull
, vol.35
, Issue.2
, pp. 458-468
-
-
Barbui, C.1
Signoretti, A.2
Mulè, S.3
Boso, M.4
Cipriani, A.5
-
41
-
-
53049101046
-
Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder
-
Houthoofd SA, Morrens M, Sabbe BG. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. Clin Ther. 2008;30(9):1565-1589.
-
(2008)
Clin Ther
, vol.30
, Issue.9
, pp. 1565-1589
-
-
Houthoofd, S.A.1
Morrens, M.2
Sabbe, B.G.3
-
42
-
-
78650943515
-
Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial
-
Cho SJ, Yook K, Kim B, et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):208-211.
-
(2011)
Prog Neuropsychopharmacol Biol Psychiatry
, vol.35
, Issue.1
, pp. 208-211
-
-
Cho, S.J.1
Yook, K.2
Kim, B.3
-
43
-
-
74449083580
-
The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double-blind randomized placebo-controlled trial
-
Abbasi SH, Behpournia H, Ghoreshi A, et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophr Res. 2010;116(2-3):101-106.
-
(2010)
Schizophr Res
, vol.116
, Issue.2-3
, pp. 101-106
-
-
Abbasi, S.H.1
Behpournia, H.2
Ghoreshi, A.3
-
44
-
-
0036490550
-
Fluvoxamine augmentation in risperidone-resistant schizophrenia: An open trial
-
Takahashi H, Sugita T, Higuchi H, Shimizu T. Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial. Hum Psychopharmacol. 2002;17(2):95-98.
-
(2002)
Hum Psychopharmacol
, vol.17
, Issue.2
, pp. 95-98
-
-
Takahashi, H.1
Sugita, T.2
Higuchi, H.3
Shimizu, T.4
-
45
-
-
67649723855
-
Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: A double-blind, randomised, placebo-controlled clinical trial
-
Berk M, Gama CS, Sundram S, et al. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. Hum Psychopharmacol. 2009;24(3)233-238.
-
(2009)
Hum Psychopharmacol
, vol.24
, Issue.3
, pp. 233-238
-
-
Berk, M.1
Gama, C.S.2
Sundram, S.3
-
46
-
-
0034014381
-
Novel antipsychotics: Issues and controversies. Typicality of atypical antipsychotics
-
Stip E. Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics. J Psychiatry Neurosci. 2000;25(2):137-153.
-
(2000)
J Psychiatry Neurosci
, vol.25
, Issue.2
, pp. 137-153
-
-
Stip, E.1
-
47
-
-
80955150801
-
Medscape
-
Available at
-
Medscape. Drugs, Diseases and Procedures: Risperidone. Available at: http://reference.medscape.com/drug/risperdal-consta-risperidone-342986#0.
-
Drugs, Diseases and Procedures: Risperidone
-
-
-
48
-
-
1542373740
-
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies
-
Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414-425.
-
(2004)
Am J Psychiatry
, vol.161
, Issue.3
, pp. 414-425
-
-
Correll, C.U.1
Leucht, S.2
Kane, J.M.3
-
49
-
-
0033065629
-
Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients
-
Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc. 1999;47(6): 716-719.
-
(1999)
J Am Geriatr Soc
, vol.47
, Issue.6
, pp. 716-719
-
-
Jeste, D.V.1
Lacro, J.P.2
Bailey, A.3
Rockwell, E.4
Harris, M.J.5
Caligiuri, M.P.6
-
50
-
-
77957267779
-
Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: Thirty-six-month results from the European schizophrenia outpatient health outcomes study
-
Novick D, Haro JM, Bertsch J, Haddad PM. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol. 2010;30(5):531-540.
-
(2010)
J Clin Psychopharmacol
, vol.30
, Issue.5
, pp. 531-540
-
-
Novick, D.1
Haro, J.M.2
Bertsch, J.3
Haddad, P.M.4
-
51
-
-
34548394992
-
Metabolic effects of atypical antipsychotics
-
Wooten J. Metabolic effects of atypical antipsychotics. South Med J. 2007;100(8):771-772.
-
(2007)
South Med J
, vol.100
, Issue.8
, pp. 771-772
-
-
Wooten, J.1
-
52
-
-
1842844950
-
American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity
-
Consensus development conference on antipsychotic drugs and obesity and diabetes
-
Consensus development conference on antipsychotic drugs and obesity and diabetes. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. J Clin Psychiatry. 2004; 65(2):267-272.
-
(2004)
J Clin Psychiatry
, vol.65
, Issue.2
, pp. 267-272
-
-
-
53
-
-
65749092920
-
Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review
-
Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry. 2009;70(7):1041-1050.
-
(2009)
J Clin Psychiatry
, vol.70
, Issue.7
, pp. 1041-1050
-
-
Simon, V.1
van Winkel, R.2
de Hert, M.3
-
54
-
-
44949234588
-
First- vs second-generation antipsychotics and risk for diabetes in schizophrenia: Systematic review and meta-analysis
-
Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K. First- vs second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2008;192(6):406-411.
-
(2008)
Br J Psychiatry
, vol.192
, Issue.6
, pp. 406-411
-
-
Smith, M.1
Hopkins, D.2
Peveler, R.C.3
Holt, R.I.4
Woodward, M.5
Ismail, K.6
-
55
-
-
77953924907
-
Hyperprolactinemia associated with psychotropics - a review
-
Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics - a review. Hum Psychopharmacol. 2010;25(4): 281-297.
-
(2010)
Hum Psychopharmacol
, vol.25
, Issue.4
, pp. 281-297
-
-
Madhusoodanan, S.1
Parida, S.2
Jimenez, C.3
-
56
-
-
68749091044
-
Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: A mixed treatment comparison of randomized controlled trials
-
Edwards SJ, Smith CJ. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials. Clin Ther. 2009;31 Pt 1:1345-1359.
-
(2009)
Clin Ther
, vol.31
, Issue.PART. 1
, pp. 1345-1359
-
-
Edwards, S.J.1
Smith, C.J.2
-
57
-
-
66749158086
-
Neuroleptic malignant syndrome associated with atypical antipsychotic drugs
-
Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs. 2009;23(6): 477-492.
-
(2009)
CNS Drugs
, vol.23
, Issue.6
, pp. 477-492
-
-
Trollor, J.N.1
Chen, X.2
Sachdev, P.S.3
-
59
-
-
0036215480
-
Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia
-
Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002;59(4):337-345.
-
(2002)
Arch Gen Psychiatry
, vol.59
, Issue.4
, pp. 337-345
-
-
Newcomer, J.W.1
Haupt, D.W.2
Fucetola, R.3
-
60
-
-
33749498006
-
Hyperlipidemia following treatment with antipsychotic medications
-
Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry. 2006;163(10):1821-1825.
-
(2006)
Am J Psychiatry
, vol.163
, Issue.10
, pp. 1821-1825
-
-
Olfson, M.1
Marcus, S.C.2
Corey-Lisle, P.3
Tuomari, A.V.4
Hines, P.5
L'Italien, G.J.6
-
61
-
-
77957923642
-
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis
-
Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2-3):225-233.
-
(2010)
Schizophr Res
, vol.123
, Issue.2-3
, pp. 225-233
-
-
Rummel-Kluge, C.1
Komossa, K.2
Schwarz, S.3
-
62
-
-
47249104675
-
The evolution of drug development in schizophrenia: Past issues and future opportunities
-
Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology. 2008;33(9):2061-2079.
-
(2008)
Neuropsychopharmacology
, vol.33
, Issue.9
, pp. 2061-2079
-
-
Carpenter, W.T.1
Koenig, J.I.2
-
63
-
-
0034598111
-
Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis
-
Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321(7273):1371-1376.
-
(2000)
BMJ
, vol.321
, Issue.7273
, pp. 1371-1376
-
-
Geddes, J.1
Freemantle, N.2
Harrison, P.3
Bebbington, P.4
-
64
-
-
0038653525
-
A meta-analysis of the efficacy of second-generation antipsychotics
-
Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60(6): 553-564.
-
(2003)
Arch Gen Psychiatry
, vol.60
, Issue.6
, pp. 553-564
-
-
Davis, J.M.1
Chen, N.2
Glick, I.D.3
-
65
-
-
33747185865
-
Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: Observational follow-up study
-
Tiihonen J, Wahlbeck K, Lönnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333(7561):224.
-
(2006)
BMJ
, vol.333
, Issue.7561
, pp. 224
-
-
Tiihonen, J.1
Wahlbeck, K.2
Lönnqvist, J.3
-
66
-
-
33751102906
-
Remission and relapse in the outpatient care of schizophrenia: Three-year results from the Schizophrenia Outpatient Health Outcomes study
-
SOHO Study Group
-
Haro JM, Novick D, Suarez D, Alonso J, Lépine JP, Ratcliffe M; SOHO Study Group. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol. 2006;26(6): 571-578.
-
(2006)
J Clin Psychopharmacol
, vol.26
, Issue.6
, pp. 571-578
-
-
Haro, J.M.1
Novick, D.2
Suarez, D.3
Alonso, J.4
Lépine, J.P.5
Ratcliffe, M.6
|